<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671825</url>
  </required_header>
  <id_info>
    <org_study_id>601-0012P</org_study_id>
    <nct_id>NCT02671825</nct_id>
  </id_info>
  <brief_title>A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Single Center, Single Group, 7-way Crossover Pilot Pharmacokinetic Study to Evaluate the Disposition of Active Component Following Single Inhaled Doses of Five Formulations of PUR0200 Compared to Reference Product in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmatrix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmatrix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare drug blood levels of multiple formulations of inhaled
      PUR0200 to each other and to the reference product with and without oral charcoal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare 5 different formulations of PUR0200 to the reference
      product. All formulations will be inhaled. In 6 of the 7 study periods either PUR0200 or the
      reference product will be inhaled under fasting conditions without oral charcoal. In the 7th
      study period, half of the subjects will receive reference with oral charcoal and the other
      half will receive reference product without oral charcoal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess PK parameter area under the plasma concentration versus time curve (AUC) of 5 formulations of PUR0200 compared to Reference Product</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess PK parameter Peak Plasma Concentration (Cmax) of 5 formulations of PUR0200 compared to Reference Product</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-related adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>self-reported and investigator-assessed adverse events, vital signs, and laboratory safety examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of PK parameters (AUC and Cmax) in subjects dosed with Reference product after ingesting charcoal and without charcoal to assess oral vs inhalation exposure of drug</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of PK parameters (AUC and Cmax) in subjects dosed with Reference product in 2 separate periods to assess the intra-subject variability of inhalation exposure to Reference product</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PUR0217a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0228a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0228b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 formulation 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0228c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 formulation 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0230c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 formulation 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Product formulation with active charcoal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Product without active charcoal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR0200</intervention_name>
    <description>PUR0200 dry powder inhalation</description>
    <arm_group_label>PUR0217a</arm_group_label>
    <arm_group_label>PUR0228a</arm_group_label>
    <arm_group_label>PUR0228b</arm_group_label>
    <arm_group_label>PUR0228c</arm_group_label>
    <arm_group_label>PUR0230c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Product</intervention_name>
    <description>Dry Powder Inhalation Reference Product</description>
    <arm_group_label>Reference Product 1</arm_group_label>
    <arm_group_label>Reference Product 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subject

          -  Age between 18 and 50 (inclusive) years

          -  Non-smokers or ex-smokers (stopped at least 6 months ago)

          -  FEV1 â‰¥80% of the predicted value

          -  Completion of 3 training inhalations

        Exclusion Criteria:

          -  Pregnant and/or nursing women. Positive pregnancy test at entry visit or on
             hospitalization day 0 of each study period.

          -  fertile women without reliable contraception

          -  participation in ANY research study within 3 months prior to entry visit, or
             simultaneous participation in another clinical study

          -  blood donation or blood loss within last 3 months

          -  treatment with ANY investigational study drug (i.e. drug not yet approved) in the last
             3 months before entry visit

          -  intake or administration of any prescribed systemic or topical medication including
             over the counter (OTC) medication or natural food supplements (e.g. vitamins, garlic,
             or ginger capsules) within 2 weeks before entry visit

          -  current or history of drug abuse within 5 years before entry visit

          -  alcohol abuse

          -  regular consumption of beverages or food containing methylxanthines (i.e. coffee, tea,
             cola, caffeine containing sodas, chocolate) equivalent to more than 500 mg
             methylxanthines* per day

          -  presence or a history of clinically significant cardiovascular, renal, hepatic,
             pulmonary, metabolic, endocrine, hematological, gastrointestinal, neurological,
             psychiatric or other diseases

          -  major surgery of the gastrointestinal tract except for appendectomy, or any pulmonary
             surgery

          -  clinically significant illness (including upper or lower respiratory infection and/or
             candidiasis of the mouth and throat) within 4 weeks before entry visit

          -  any acute or chronic disease which might interfere with inhalation, absorption,
             distribution, metabolism or excretion of the drug special diet due to any reason, e.g.
             vegetarians

          -  positive serologic findings for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies

          -  excessive physical activity (more than 4 times per week for more than 90 minutes)
             within the last 6 months and during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentin Kirkov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokuda Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hava, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pulmatrix Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

